pacira.com (PCRX): Net earnings per share growth forecast for next year
The growth of Pacira BioSciences (PCRX) relies on the expansion of Exparel into clinics and the level of insurance reimbursements. The trend in consensus earnings per share estimates reflects expert expectations, where the value of 21.10 characterizes this level. High patent barriers and the specifics of surgeon training protect the firm's position, while streamlined supply chains via specialized hubs guarantee the uninterrupted distribution of drugs.
Analytical breakdowns for Pacira BioSciences
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Capital Pacira BioSciences|PCRX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Pacira BioSciences, Inc.|PCRX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Pacira BioSciences|PCRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Pacira BioSciences|Quick Liquidity Indicator pacira.com
- net income and valuation ratios data:
PCRX - Final Profit|Projected Future Earnings Pacira BioSciences|PCRX - Price to Earnings Ratio|Forward P/E Multiple Pacira BioSciences|PCRX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pacira BioSciences|PCRX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Pacira BioSciences|PCRX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth pacira.com|PCRX - Net earnings per share growth this year|Earnings growth forecast for next year Pacira BioSciences
Initial company analysis:PCRX, Pacira
The profitability of the Pacira BioSciences (PCRX) EXPAREL ecosystem depends directly on Medicare reimbursement codes and FDA decisions, which determine the current value of 21.10. This indicator measures consolidated market expectations for earnings per share, where a steady rise based on the company's next-year EPS dynamics confirms the business's ability to scale, while sharp spikes signal a risk of asset overvaluation.
Competitor analysis for Pacira BioSciences
HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand LGND|AMRX (Amneal Pharmaceuticals, Inc.) - Net earnings per share change forecast for next year|Perrigo Company - Earnings growth forecast for next year|ALVO - Earnings growth forecast for next year|LQDA: Earnings growth forecast for next year|Expected earnings per share growth for next year glpg.com|ANIP (ANI Pharmaceuticals, Inc.) - Earnings growth forecast for next year|MannKind Corp (MNKD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amphastar (AMPH)|SPRY (ARS Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year TBPH (Theravance Biopharma)|Earnings growth forecast for next year aquestive.com AQST|SCPH: Expected earnings per share growth for next year|Expected earnings per share trend next year TECX (Tectonic Therapeutic, Inc.)|TNXP: Earnings growth forecast for next year|SXTC (China SXT Pharmaceuticals, Inc.) - Net earnings per share growth forecast for next year|EPRX (Eupraxia Pharmaceuticals, Inc.) - Earnings growth forecast for next year|bioharvest.com (BHST) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year eXoZymes (EXOZ)|ORMP - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Entera Bio ENTX|Consensus forecast of earnings per share growth for next year MindWalk Therapeutics (HYFT)|ABVC BioPharma - Earnings growth forecast for next year|cumberlandpharma.com (CPIX) - Expected earnings per share growth for next year|QNTM: Earnings growth forecast for next year|FGEN - Consensus forecast of earnings per share growth for next year|TELO (Telomir Pharma) - Earnings growth forecast for next year|Expected net earnings per share growth next year Rani Therapeutics Inc RANI|Net earnings per share growth forecast for next year Synergy CHC Corp (SNYR)|rallybio.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year LEXX (Lexaria Bioscience Corp.)|PULM - Expected earnings per share growth for next year|Pheton - Earnings growth forecast for next year|Expected net earnings per share growth next year Aptorum Group Limited|Lyra Therapeutics, Inc. (LYRA) - Net earnings per share growth forecast for next year|IBO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals Inc.|cbdMD Corp - Net earnings per share change forecast for next year|Earnings growth forecast for next year PRFX|Expected earnings per share growth for next year altamiratherapeutics.com CYTO|Net earnings per share growth forecast for next year Lipella Pharmaceuticals LIPO|Expected earnings per share trend next year OPTN|PIRS: Expected earnings per share growth for next year|PROC (Procaps Group) - Projected earnings per share growth rate for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International Corp)|SLRN (Acelyrin, Inc.) - Earnings growth forecast for next year|TFFP: Expected earnings per share trend next year
